Biomarkers · Inflammation
Immunoglobulin M (IgM)
The published study could not tell whether risk rises or falls: its 95% interval includes no change. No risk curve catalogued yet.
Published risk of death1.01×per 1 SD increase in IgM (95% CI 0.96–1.06) · Meta-analysis of Augsburg MONICA/KORA, MONICA Glasgow, Speedwell and one other published study with baseline Ig levels (n=8218)
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in IgM, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Bezafibrate plus ursodeoxycholic acid vs ursodeoxycholic acid alone in patients with primary biliary cirrhosis | Plasma IgM fell 164.00 mg/dL (95% CI -259.47 to -68.53) with bezafibrate vs no intervention, duration not stated; 3 trials, n=50 | meta-analysis | Rudic JS, et al. Cochrane Database Syst Rev. 2012;1:CD009145. |